Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients
Recruitment status was: Recruiting
|Recurrent Nasopharyngeal Carcinoma|
|Study Design:||Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
|Study Start Date:||April 2006|
|Estimated Study Completion Date:||June 2006|
Nasopharyngeal carcinomas (NPCs) are highly radiosensitive tumors, and the primary treatment of NPCs is radiotherapy.1 Because most patients who have NPC are at advanced stages when initially seen, local failures in terms of persistence or recurrence are not infrequent after primary radiotherapy.2,3 Local regional relapse without the presence of distant failure can still be salvaged and should be aggressively treated. Tumors relapsing in the nasopharynx can be salvaged using either re-irradiation or surgical techniques.1 Although re-irradiation to the recurrent tumor can extent the 5-year actuarial survival rate, it is associated with high morbidity. 4-6 Traditional nasopharyngectomy has been associated with local control rates on the order of 40%~50%, but it has also been associated with complications such as palatal defects, trismus, facial scarring, osteomyelitis, etc.7-10 That is the reason why surgeons continue searching for new methods for performing nasopharyngectomies with lower morbidities.
Nasopharyngectomies are difficult to perform because of the inaccessibility of the nasopharynx. More difficulties are encountered in performing a nasopharyngectomy through the nose due to the restricted surgical field. With advances in techniques of endoscopy and application of the potassium-titanyl-phosphate (KTP) laser in surgery, pathologic lesions located either at the choanal margin or in the nasopharynx can easily be managed with instruments inserted via the nasal cavities. The surgical technique had been accepted by the authority journal. This time, we will review the therapeutic result of KTP-laser nasopharyngectomy in patients with recurrent NPC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00364962
|Contact: Ching-Ting Tan, MD, PhD||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Contact: Ching-Ting Tan, MD, PhD 886-2-23123456 ext 5222 firstname.lastname@example.org|
|Principal Investigator:||Ching-Ting Tan, MD, PhD||National Taiwan University Hospital|